Nir Barzilai

Nir Barzilai

Auto-generated profile, based on publicly available information

Nir Barzilai

Department of Medicine, Institute for Aging Research, Albert Einstein College of Medicine , Bronx, NY, United States

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Cell Metabolism
Verified
Journal Article
Closed access
AKAmeya Kulkarni
Ameya Kulkarni
SGSriram Gubbi
Sriram Gubbi
NBNir Barzilai
Nir Barzilai

4 March 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YSYousin Suh
Yousin Suh
Gil AtzmonGil Atzmon
Gil Atzmon
MCMi-Ook Cho
Mi-Ook Cho
DHDavid Hwang
David Hwang
BLBingrong Liu
Bingrong Liu
PCPinchas Cohen
Pinchas Cohen
Rather than being a passive, haphazard process of wear and tear, lifespan can be modulated actively by components of the insulin/insulin-like growth factor I (IGFI) pathway in laboratory animals. Complete or partial loss-of-function mutations in genes encoding components of the insulin/IGFI pathway result in extension of life span in yeasts, worms, flies, and mice. This remarkable conservation throughout evolution suggests that altered signaling in this pathway may also influence human lifespan. On the other hand, evolutionary tradeoffs predict that the laboratory findings may not be relevant to human populations, because of the high fitness cost during early life. Here, we studied the biochemical, phenotypic, and genetic variations in a cohort of Ashkenazi Jewish centenarians, their offspring, and offspring-matched controls and demonstrated a gender-specific increase in serum IGFI associated with a smaller stature in female offspring of centenarians. Sequence analysis of the IGF1 and IGF1 receptor ( IGF1R ) genes of female centenarians showed overrepresentation of heterozygous mutations in the IGF1R gene among centenarians relative to controls that are associated with high serum IGFI levels and reduced activity of the IGFIR as measured in transformed lymphocytes. Thus, genetic alterations in the human IGF1R that result in altered IGF signaling pathway confer an increase in susceptibility to human longevity, suggesting a role of this pathway in modulation of human lifespan.

15 October 2003 in JAMA
Verified
Journal Article
Open access
PDF file
NBNir Barzilai
Nir Barzilai
GAGil Atzmon
Gil Atzmon
CSClyde Schechter
Clyde Schechter
ESErnst J. Schaefer
Ernst J. Schaefer
ACAdrienne L. Cupples
Adrienne L. Cupples
ASAlan R. Shuldiner
Alan R. Shuldiner
Individuals with exceptional longevity have been generally spared from major age-related diseases that are responsible for most deaths in elderly persons, such as cardiovascular disease (CVD), diabetes mellitus, Alzheimer disease, and cancer.1 Various studies suggest that genetic determinants of exceptional longevity are highly heritable.2,3 Siblings of centenarians have an 8- to 17-fold higher probability of living past the age of 100 years, accounting for only approximately 1 of 10 000 individuals in the general population.2,3 The offspring of long-lived parents have an approximately 50% lower prevalence of hypertension, diabetes mellitus, myocardial infarction, and stroke/transient ischemic attacks compared with age-matched control groups.3 Furthermore, at least 1 study linked a locus on chromosome 4 to exceptional longevity.4 Identification of biological markers and genes that are conducive to exceptional longevity may provide insights into mechanisms that protect from a host of common diseases and/or slow the biological processes of aging.

1 January 1999 in Diabetes
Verified
Journal Article
Closed access
PDF file
NBN Barzilai
N Barzilai
LSL She
L She
BLB Q Liu
B Q Liu
PVP Vuguin
P Vuguin
PCP Cohen
P Cohen
LRL Rossetti
L Rossetti
We directly examined whether visceral fat (VF) modulates hepatic insulin action by randomizing moderately obese (body wt approximately 400 g) Sprague-Dawley rats to either surgical removal of epididymal and perinephric fat pads (VF-; n = 9) or a sham operation (VF+; n = 11). Three weeks later, total VF was fourfold increased (8.5 +/- 1.2 vs. 2.1 +/- 0.3 g, P < 0.001) in the VF+ compared with the VF- group, but whole-body fat mass (determined using 3H2O) was not significantly different. The rates of insulin infusion required to maintain plasma glucose levels and basal hepatic glucose production in the presence of hepatic-pancreatic clamp were markedly decreased in VF- compared with VF+ rats (0.57 +/- 0.02 vs. 1.22 +/- 0.19 mU x kg(-1) x min(-1), P < 0.001). Similarly, plasma insulin levels were more than twofold higher in the VF+ group (P < 0.001). The heightened hepatic insulin sensitivity is supported by the decrease in gene expression of both glucose-6-phosphatase and PEPCK and by physiological hyperinsulinemia in VF- but not VF+ rats. The improvement in hepatic insulin sensitivity in VF- rats was also supported by a approximately 70% decrease in the plasma levels of insulin-like growth factor binding protein-1, a marker of insulin's transcription regulation in the liver. The removal of VF pads also resulted in marked decreases in the gene expression of tumor necrosis factor-alpha (by 72%) and leptin (by 60%) in subcutaneous fat. We conclude that visceral fat is a potent modulator of insulin action on hepatic glucose production and gene expression.

21 July 2009 in Aging Cell
Verified
Journal Article
Open access
PDF file
LPLudmila Pawlikowska
Ludmila Pawlikowska
DHDonglei Hu
Donglei Hu
SHScott Huntsman
Scott Huntsman
ASAndrew Sung
Andrew Sung
CCCatherine Chu
Catherine Chu
FFfor the Study of Osteoporotic Fractures
for the Study of Osteoporotic Fractures
Summary: The insulin/IGF1 signaling pathways affect lifespan in several model organisms, including worms, flies and mice. To investigate whether common genetic variation in this pathway influences lifespan in humans, we genotyped 291 common variants in 30 genes encoding proteins in the insulin/IGF1 signaling pathway in a cohort of elderly Caucasian women selected from the Study of Osteoporotic Fractures (SOF). The cohort included 293 long‐lived cases (lifespan ≥ 92 years (y), mean ± standard deviation (SD) = 95.3 ± 2.2y) and 603 average‐lifespan controls (lifespan ≤ 79y, mean = 75.7 ± 2.6y). Variants were selected for genotyping using a haplotype‐tagging approach. We found a modest excess of variants nominally associated with longevity. Nominally significant variants were then replicated in two additional Caucasian cohorts including both males and females: the Cardiovascular Health Study and Ashkenazi Jewish Centenarians. An intronic single nucleotide polymorphism in AKT1, rs3803304, was significantly associated with lifespan in a meta‐analysis across the three cohorts (OR = 0.78 95%CI = 0.68–0.89, adjusted P = 0.043); two intronic single nucleotide polymorphisms in FOXO3A demonstrated a significant lifespan association among women only (rs1935949, OR = 1.35, 95%CI = 1.15–1.57, adjusted P = 0.0093). These results demonstrate that common variants in several genes in the insulin/IGF1 pathway are associated with human lifespan.

1 April 1998 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NBN Barzilai
N Barzilai
SBS Banerjee
S Banerjee
MHM Hawkins
M Hawkins
WCW Chen
W Chen
LRL Rossetti
L Rossetti
Hyperinsulinemia and increased visceral/abdominal fat (VF) are common features of human aging. To examine the relationships among VF, peripheral, and hepatic insulin sensitivity, we studied 4- and 18-mo-old male Sprague-Dawley rats (n = 42) fed ad libitum (4 AL and 18 AL) or moderately calorie restricted (18 CR) up to 18 mo of age. Total fat mass (FM) and VF were decreased in 18 CR to approximately one-third of that of 18 AL (P < 0.001), while lean body mass (LBM) was unchanged. Most important, 18 CR had more FM (65+/-6 vs. 45+/-6 g) but less VF (7.8+/-0.6 vs. 12.3+/-3.3 g) compared with 4 AL (P < 0.01 for both). Thus, the effects of variable VF on HIS could be assessed, independent of FM and age. Marked hepatic insulin resistance ensued with aging (18 AL) and CR restored hepatic insulin sensitivity to the levels of young rats, while peripheral insulin sensitivity remained unchanged (by insulin clamp of 18 mU/kg/min). In fact, the rates of insulin infusion required to maintain basal hepatic glucose production in the presence of pancreatic clamp were 0.75+/-0.10, 1.41+/-0.13, and 0.51+/-0.12 mU/kg . min, in 4 AL, 18 AL, and 18 CR, respectively (P < 0.01 between all groups), and in 18 CR rats infused with insulin at similar rates as in the 18 AL (1.4 mU/kg/min) hepatic glucose production was decreased by 32% (P < 0. 005). Furthermore, when 18 CR rats were fed AL for 14 d, VF rapidly and selectively increased and severe hepatic insulin resistance was induced. We propose that in this animal model the age-associated decrease in hepatic (rather than peripheral) insulin action is the major determinant of fasting hyperinsulinemia and that increased visceral adiposity plays the major role in inducing hepatic insulin resistance. Thus, interventions designed to prevent the accumulation of VF are likely to represent an effective mean to improve carbohydrate metabolism in aging.